Tailored testing

The Tempus algorithmic test platform leverages our molecular and clinical database, CAP/CLIA lab, and clinician network to offer tests that help inform the treatment of cancer patients.

IPS Test

The Tempus Immune Profile Score (IPS) is a multimodal biomarker that can be used as a prognostic indicator for adult patients with metastatic and/or stage IV pan-solid tumor disease who are already considered candidates for immune checkpoint inhibitor (ICI) based therapy.

IPS uses DNA and RNA sequencing data from the Tempus xT and xR tests to classify patients as IPS-High or IPS-Low. Patients classified as IPS-High were found to have a higher real world overall survival (rwOS) compared to those with an IPS-Low result when treated with ICI-based regimens. IPS may provide enhanced insights complementary to standard biomarker testing used today.

Tempus IPS Advantages

HRD Test

Tempus HRD is a laboratory developed test to predict the probability of a patient’s cancer having a phenotype characterized by the inability to repair DNA breaks via the homologous recombination repair (HRR) pathway, known as homologous recombination deficiency (HRD). It is available as an additional test for patients who are tested with Tempus xT or xR.

For ovarian and breast cancer, where DNA based methods of HRD detection are common or under investigation, Tempus HRD provides a result based on DNA genome-wide loss of heterozygosity (GWLOH) or evidence of biallelic BRCA1 or BRCA2 loss from the xT test. For patients with other cancers, Tempus HRD provides an HRD score based on 1,660 gene RNA expression using data from the xR test.

Tempus HRD Advantages

*xT solid tumor + normal match DNA seq required for breast and ovarian cancer HRD testing. All other cancers require xR RNA seq.

TO Test

The Tempus Tumor Origin (TO) test uses tumor RNA expression results to predict the patient’s most likely cancer type(s) from 68 possible cancer types. The Tempus TO test was developed using a large internal database of clinical and annotated molecular tumor data.

The intended use of the TO test is for cancers of unknown primary and cases for which the available diagnostic information, such as imaging and immunohistochemistry results, do not provide a definitive diagnosis. When paired with xR, the TO results may provide insight into the patient’s diagnosis and tumor site of origin that may be used to inform patient care and clinical trial eligibility.

Tempus TO Advantages

PurIST® Test

Tempus’ PurIST® test is a laboratory developed test that uses an RNA-based algorithm to classify pancreatic ductal adenocarcinomas (PDAC) into one of two subtypes (basal-like or classical).

Published literature using the PurIST® algorithm with non-Tempus RNA sequencing data indicates that patients with the basal subtype have a worse prognosis and are less likely to benefit from FOLFIRINOX therapy than classical patients.¹

Tempus independently validated use of the PurIST® algorithm with Tempus RNA sequencing data which demonstrated subtype stratification with distinct survival outcomes and treatment benefit, supporting the integration of PurIST® into routine clinical care for patients with advanced PDAC to inform first-line chemotherapy selection.²

Tempus PurIST® Advantages

Clinical biomarker testing supports treatment selection and clinical decision-making across tumor types. These tests are ordered alongside genomic profiling and are reported within the same integrated Tempus result.

PGx testing identifies genetic variants that may influence how individual patients metabolize certain therapies — enabling providers to assess potential toxicity risk before treatment begins with rapid results in 3-5 days.

DPYD Test
Covers all tier 1 variant alleles in DPYD pharmacogene, to assess metabolic status. Results can help to identify patients at elevated risk for toxicity to medications such as 5-FU and/or capecitabine.³

UGT1A1 Test
Covers key variants in UGT1A1 pharmacogene to assess metabolic status. Results can help to identify patients at elevated risk for toxicity to medications such as irinotecan, sacituzumab govitecan, and/or belinostat.

RightMed® Comprehensive
Reports metabolic status for 27 genes, including DPYD and UGT1A1, as well as genotype-predicted interactions for an array of medications.

ArteraAI Prostate Test (mHSPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) patients are typically categorized as high- or low-volume, but these categories may not fully capture the nature of the disease that may aid in treatment intensity decisions, such as doublet or triplet therapy. The ArteraAI Prostate Test (mHSPC) uses multimodal artificial intelligence (MMAI) to analyze clinical data alongside existing H&E biopsy slides to deliver a validated, patient-specific 5-year prostate cancer–specific mortality (PCSM) risk estimate.

ArteraAI Prostate Test (mHSPC) is intended for newly diagnosed, treatment-naïve mHSPC patients.

ArteraAI Advantages

• No additional tissue required; may be ordered as an add-on with xT CDx, xT Solid Tumor Only, or xR RNA seq.
• Can provide more information for patients where disease aggressiveness is uncertain at diagnosis. Low-volume presentations where standard staging may underestimate risk and patients where an individualized MMAI score and/or a PCSM risk estimate with standard doublet therapy would support the clinical conversation

1. Rashid NU, et al. Purity independent subtyping of tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer. Clin Cancer Res. 2020;26(1):82-92. doi:10.1158/1078-0432.CCR-19-1467.
2. Wenric S, Sangli C, Guittar J, et al. Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection in Pancreatic Ductal Adenocarcinoma. JCO Precis Oncol. 2025;9:e2500197. doi:10.1200/PO-25-00197
3. Pratt VM, Cavallari LH, Fulmer ML, et al. DPYD genotyping recommendations. J Mol Diagn. 2024;26(10):851-863.